Anticoagulation control in Malaysia: Reports of time in therapeutic range, bleeding, and thromboembolic complications

被引：0
|
作者：
Mazlan-Kepli, W. [1 ]
Mohamed, S. [2 ]
Nik-Ismail, N. A. [3 ]
Nagarajah, J. R. [4 ]
机构：
[1] Univ Malaya, Dept Clin Pharm & Pharm Practice, Fac Pharm, Kuala Lumpur 50603, Malaysia
[2] Minist Hlth Malaysia, Hosp Serdang, Dept Pharm, Jalan Puchong, Kajang 43000, Selangor, Malaysia
[3] Minist Hlth Malaysia, Hosp Raja Perempuan Zainab II, Dept Pharm, Jalan Hosp, Kota Baharu 15200, Kelantan, Malaysia
[4] Minist Hlth Malaysia, Hosp Kuala Lumpur, Dept Pharm, Jalan Pahang, Kuala Lumpur 50586, Wilayah Perseku, Malaysia
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2022年 / 369卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
24
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [41] Time in Therapeutic Range Redefining Blood Pressure Control
    Bakris, George
    Sternlicht, Hillel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (10) : 1300 - 1301
  • [42] Thromboembolic and bleeding complications following St. Jude medical valve replacement - Results of the German experience with low-intensity anticoagulation study
    Hering, D
    Piper, C
    Bergemann, R
    Hillenbach, C
    Dahm, A
    Huth, C
    Horstkotte, D
    CHEST, 2005, 127 (01) : 53 - 59
  • [43] Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study
    Ording, Anne G.
    Horvath-Puho, Erzsebet
    Adelborg, Kasper
    Pedersen, Lars
    Prandoni, Paolo
    Sorensen, Henrik T.
    CANCER MEDICINE, 2017, 6 (06): : 1165 - 1172
  • [44] Development and implementation of time in Therapeutic Range reports within the Veterans health administration
    Tran, Michael
    Parra, David
    Meier, Joy
    Clark, Christine
    Morreale, Anthony
    PHARMACOTHERAPY, 2017, 37 (12): : E218 - E219
  • [45] The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation
    Pfeilschifter, Waltraud
    Luger, Sebastian
    Brunkhorst, Robert
    Lindhoff-Last, Edelgard
    Foerch, Christian
    CEREBROVASCULAR DISEASES, 2013, 36 (02) : 115 - 119
  • [46] Quality assessment of anticoagulation dose management: Comparative evaluation of measures of time-in-therapeutic range
    Schmitt, L
    Speckman, J
    Ansell, J
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2003, 15 (03) : 213 - 216
  • [47] Determinants of Good and Poor Quality Oral Anticoagulation Assessed By Time in Therapeutic INR Range (TTR)
    Costa, Gustavo
    Moraes, Eduardo
    Valacio, Reginaldo
    Calosimo, Enrico
    Moreira, Maria Da Consolacao
    CIRCULATION, 2010, 122 (02) : E213 - E213
  • [48] Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range
    L. Schmitt
    J. Speckman
    J. Ansell
    Journal of Thrombosis and Thrombolysis, 2003, 15 : 213 - 216
  • [49] Impact of provision of time in therapeutic range value on anticoagulation management in atrial fibrillation patients on warfarin
    Huang, Duo
    Wong, Chi-Lap
    Cheng, Kwan-Wa
    Chan, Pak-Hei
    Yue, Wen-Sheng
    Wong, Chun-Ka
    Ho, Chi-Wai
    Wong, Ian C. K.
    Chan, Esther W.
    Siu, Chung Wah
    POSTGRADUATE MEDICAL JOURNAL, 2018, 94 (1110) : 207 - 211
  • [50] Effect of increased time in the therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service
    Phelps, Elise
    Delate, Thomas
    Witt, Daniel M.
    Shaw, Paul B.
    McCool, Kathleen H.
    Clark, Nathan P.
    THROMBOSIS RESEARCH, 2018, 163 : 54 - 59
12345